Does NIVOLUMAB Cause Immune-mediated enterocolitis? 1,289 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 1,289 reports of Immune-mediated enterocolitis have been filed in association with NIVOLUMAB (OPDIVO). This represents 1.5% of all adverse event reports for NIVOLUMAB.
1,289
Reports of Immune-mediated enterocolitis with NIVOLUMAB
1.5%
of all NIVOLUMAB reports
111
Deaths
669
Hospitalizations
How Dangerous Is Immune-mediated enterocolitis From NIVOLUMAB?
Of the 1,289 reports, 111 (8.6%) resulted in death, 669 (51.9%) required hospitalization, and 122 (9.5%) were considered life-threatening.
Is Immune-mediated enterocolitis Listed in the Official Label?
Yes, Immune-mediated enterocolitis is listed as a known adverse reaction in the official FDA drug label for NIVOLUMAB.
What Other Side Effects Does NIVOLUMAB Cause?
Death (11,216)
Malignant neoplasm progression (9,363)
Off label use (5,208)
Diarrhoea (4,692)
Fatigue (3,709)
Pyrexia (3,454)
Intentional product use issue (3,297)
Rash (2,816)
Nausea (2,805)
Decreased appetite (2,619)
What Other Drugs Cause Immune-mediated enterocolitis?
IPILIMUMAB (988)
PEMBROLIZUMAB (858)
CARBOPLATIN (307)
PACLITAXEL (188)
DURVALUMAB (165)
ATEZOLIZUMAB (156)
LENVATINIB (143)
PEMETREXED (129)
BEVACIZUMAB (92)
TREMELIMUMAB\TREMELIMUMAB-ACTL (63)
Which NIVOLUMAB Alternatives Have Lower Immune-mediated enterocolitis Risk?
NIVOLUMAB vs NIVOLUMAB\RELATLIMAB-RMBW
NIVOLUMAB vs NIZATIDINE
NIVOLUMAB vs NOMEGESTROL
NIVOLUMAB vs NORDAZEPAM
NIVOLUMAB vs NOREPINEPHRINE